Exhibit 99.1

Calyxt Reports Financial Results for Third Quarter 2018

90% of High-Oleic Soybean Acres Harvested To-Date in Fall 2018

Over 17,000 High-Oleic Soybean Acres Contracted for 2019 Growing Season Already Exceeding Last Year’s Acres

Agreement with American Natural Processors to Crush and Process High-Oleic Soybeans

Agreement with KemX Global to Refine High-Oleic Soybean Oil – Refining Capacity to Scale Up

30 Food Companies Engaged – 3 in Advanced Discussions

Successful Harvest of High-Fiber Wheat Field Trials

Appointed new CEO, Jim Blome, Former President & CEO of Bayer CropScience LP

Cash and Cash Equivalents Position of $101.8M as of September 30, 2018

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--November 13, 2018--Calyxt, Inc. (NASDAQ:CLXT), a consumer-centric, food- and agriculture-focused company, today announced its results for the three- and nine-month periods ended September 30, 2018.

Investor Call Details

Calyxt will host an investor call on November 14, 2018 at 8:00 am Eastern Time – 7:00 am Central Time to discuss its financial results and provide a general business update.

The live dial-in information for the conference call is:

US & Canada only: 877-407-9747
International: 412-902-0044

In addition, a replay of the call will be available until May 14, 2019 by calling 877-660-6853 (Toll Free US & Canada); 201-612-7415 (Toll Free International).

Webcast URL (Archived for 6 months): http://bit.ly/2DbCETf

“The third quarter of 2018 was an exciting and crucial time for Calyxt to take important steps towards the commercialization of our lead product candidate, a non-GMO, high oleic soybean variety, designed to yield soybean oil with over 80% oleic oil content that is completely trans-fat free. Our partnerships with American Natural Processors, which will crush and process our high-oleic soybeans, and KemX Global, which will refine our oil, will position us to grow significantly. On the farmer side, we are hitting the ground running with our upcoming high-oleic soybean growing season. I am pleased to announce that within the first few weeks of contracting for 2019, we have already surpassed Calyxt’s acreage for all of 2018. On the food customer front, we are in discussions with over 30 food companies, from small to multi-national. In summary, I can say that we are well on track to becoming a real commercial player,” said Jim Blome, newly appointed CEO of Calyxt. “Furthermore, I am beyond thrilled to be a part of such an amazing team at this very moment in time, ringing in a new era in the field of agriculture. Our TALEN®-technology platform, our world class scientists and lab facilities, our U.S. regulatory position and our extensive IP assets are just some of the reasons that enticed me to take on this new role. In addition, our product pipeline is well-suited for today’s consumer trends demanding healthier diets, food supply transparency, improved taste and the sustainability of food production by lowering inputs and waste.”

High Oleic Soybean Update:

Agreement with KemX Global, a leading provider of innovative organic processing of oils, to refine Calyxt’s high-oleic soybean oil. KemX Global’s organic, non-GMO-certified Iowa plant positions Calyxt to work with multiple crush plants in the Midwest region and positions Calyxt’s supply chain for the production of our food-grade high-oleic soybean oil.

Pipeline Update:

Corporate Update:

Financial Highlights

Cash and cash equivalents were $101.8 million at September 30, 2018. We intend to continue to judiciously manage the use of cash and expect to have sufficient cash to fund the business until late 2020.

For the three months ended September 30, 2018, we incurred losses from operations of $7.7 million and used net cash in operating activities of $4.8 million.

For the nine months ended September 30, 2018, we incurred losses from operations of $19.5 million and used net cash in operating activities of $13.6 million. Our cash spend for the first nine months of 2018 can be broken into 3 categories:

We anticipate that our operating cash spend will be in the range of $2.0 million per month on average in 2018.

Calyxt, Inc.
Condensed Balance Sheets
(Amounts in Thousands, Except Share Data and Per Share Data)
  September 30,   December 31,
2018 2017
Current assets:
Cash and cash equivalents $ 101,796 $ 56,664
Restricted cash 50
Trade accounts receivable
Due from related parties 166 167
Prepaid expenses and other current assets   967     626  
Total current assets 102,979 57,457
Property and equipment, net 21,305 14,353
Other long-term assets   341     357  
Total assets $ 124,625   $ 72,167  
Liabilities and stockholders’ equity
Current liabilities:
Due to related parties $ 1,937 $ 1,350
Accounts payable 1,240 1,023
Accrued salaries, wages, and other compensation 1,016 945
Accrued liabilities 2,669 893
Current deferred revenue 7 43
Total current liabilities 6,869 4,254
Non-current deferred revenue 91 289
Finance lease obligations and other long term liabilities 17,433 10,148
Total liabilities 24,393 14,691
Stockholders’ equity:

Common stock, $0.0001 par value; 275,000,000 shares authorized, 32,463,407 and 27,718,780
shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively

3 3
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, no shares
issued or outstanding as of September 30, 2018 and December 31, 2017, respectively
Additional paid-in capital 174,206 112,021
Accumulated deficit (73,977 ) (54,548 )
Total stockholders’ equity   100,232     57,476  
Total liabilities and stockholders’ equity $ 124,625   $ 72,167  

Calyxt, Inc.
Condensed Statements of Operations
(Amounts in Thousands except Shares Outstanding and Per Share Amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
  2018       2017     2018       2017  
(unaudited) (unaudited)
Revenue $ 27 $ 44 $ 234 $ 322
Operating expenses:
Cost of revenue
Research and development 3,307 6,438 7,493 9,157
Selling, general, and administrative   4,419     6,553     12,228     10,141  
Total operating expenses   7,726     12,991     19,721     19,298  
Loss from operations (7,699 ) (12,947 ) (19,487 ) (18,976 )
Interest income, net 228 48 88 4
Foreign currency transaction loss   (12 )   (5 )   (30 )   (159 )
Loss before income taxes (7,483 ) (12,904 ) (19,429 ) (19,131 )
Income tax expense                
Net loss $ (7,483 ) $ (12,904 ) $ (19,429 ) $ (19,131 )
Basic and diluted loss per share $ (0.23 ) $ (0.51 ) $ (0.65 ) $ (0.89 )
Weighted average shares outstanding—basic and diluted $ 32,381,010   $ 25,531,572   $ 30,040,926   $ 21,615,703  

Calyxt, Inc.
Condensed Statement of Stockholders’ Equity
(Amounts in Thousands except Shares Outstanding)










Balances at December 31, 2017 27,718,780 $ 3 $ 112,021 $ (54,548 ) $ 57,476
Net loss (19,429 ) (19,429 )
Common shares issued upon exercise of options and other 687,127 2,128 2,128
Stock-based compensation 3,016 3,016
Issuance of common stock 4,057,500     57,041     57,041  
Balances at September 30, 2018 (unaudited) 32,463,407 $ 3 $ 174,206 $ (73,977 ) $ 100,232  

Calyxt, Inc.
Condensed Statements of Cash Flows
(Amounts in Thousands)
  Nine Months Ended
September 30,
  2018       2017  
Operating activities
Net loss $ (19,429 ) $ (19,131 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation 727 414
Stock-based compensation 3,016 9,980
Unrealized transaction gain (loss) on related party activity 12 (8 )
Changes in operating assets and liabilities:
Trade accounts receivable 110
Due to/from related parties 576 1,534
Prepaid expenses and other assets (325 ) (260 )
Accounts payable 217 205
Accrued salaries, wages, and other compensation 70 160
Accrued liabilities 1,770 1,250
Deferred revenue   (234 )   (222 )
Net cash used in operating activities (13,600 ) (5,968 )
Investing activities
Purchases of property and equipment, net (830 ) (1,614 )
Net cash used in investing activities (830 ) (1,614 )
Financing activities
Advances from Cellectis 3,000
Repayment of advances from Cellectis (3,000 )
Costs incurred related to the issuance of stock (222 ) (3,330 )
Proceeds from common stock issuance 57,706 61,292
Proceeds from the exercise of stock options 2,128 182
Financing lease obligation       6,957  
Net cash provided by financing activities   59,612     65,101  
Net increase in cash, cash equivalents and restricted cash 45,182 57,519
Cash, cash equivalents and restricted cash—beginning of period   56,664     5,026  
Cash, cash equivalents and restricted cash—end of period $ 101,846   $ 62,545  
Supplemental cash flow information
Interest paid $ 856 $ 44
Supplemental non-cash investing and financing transactions:
Property and equipment included in financing lease obligations $ 6,849
Offering costs in accounts payable and accrued liabilities $ 443 $ 2,081

The following presents cash, cash equivalents and restricted cash by category within the condensed balance sheet:

Cash and cash equivalents $ 101,796 $ 62,545
Restricted cash   50      
Total $ 101,846   $ 62,545  

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.

Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@calyxt.com

Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212.896.1241 / 212.896.1206
email: ckasunich@kcsa.com / nopich@kcsa.com

Investor Relations
Simon Harnest, VP Corporate Strategy and Finance
Phone: 646-385-9008
email: simon.harnest@calyxt.com